www.nrxpharma.com Open in urlscan Pro
2620:12a:8001::4  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
Primary Menu
 * Our Company
 * Our Therapeutic Focus
   * Our Focus on the Brain
   * Bipolar Depression & Suicidality
   * Post-Traumatic Stress Disorder
   * Respiratory
 * Our Science
   * Our Clinical Approach
   * NRX-100/NRX-101
   * Mechanism of Action
   * NMDA & 5HT2A receptors
   * Publications & Literature
 * Our Pipeline
 * Investors / Media

 * Investor Relations
 * Presentation
 * Clinical Trials
 * Search




HOME


HOPE • SCIENCE • LIFE

Previous


RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more


RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more



WE BRING
HOPE TO LIFE

People facing life-threatening diseases need the possibility of tomorrow. We
bring them hope through life-saving medicines.


WE BRING
HOPE TO LIFE

People facing life-threatening diseases need the possibility of tomorrow. We
bring them hope through life-saving medicines.




STERN CORPORATE ACCESS EVENT FOR INVESTORS AT THE 41ST J.P. MORGAN HEALTHCARE
CONFERENCE

Learn More


STERN CORPORATE ACCESS EVENT FOR INVESTORS AT THE 41ST J.P. MORGAN HEALTHCARE
CONFERENCE

Learn More



DISCOVER OUR PIPELINE

We go after the most critical medical conditions and unmet needs.

Learn more


DISCOVER OUR PIPELINE

We go after the most critical medical conditions and unmet needs.

Learn more



RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more


RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more



WE BRING
HOPE TO LIFE

People facing life-threatening diseases need the possibility of tomorrow. We
bring them hope through life-saving medicines.


WE BRING
HOPE TO LIFE

People facing life-threatening diseases need the possibility of tomorrow. We
bring them hope through life-saving medicines.




STERN CORPORATE ACCESS EVENT FOR INVESTORS AT THE 41ST J.P. MORGAN HEALTHCARE
CONFERENCE

Learn More


STERN CORPORATE ACCESS EVENT FOR INVESTORS AT THE 41ST J.P. MORGAN HEALTHCARE
CONFERENCE

Learn More



DISCOVER OUR PIPELINE

We go after the most critical medical conditions and unmet needs.

Learn more


DISCOVER OUR PIPELINE

We go after the most critical medical conditions and unmet needs.

Learn more



RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more


RESOURCES & PATIENT STORIES

We aim to develop innovative, life-saving treatments and thereby bring hope to
those facing life-altering conditions with no approved therapies.

Click here for Bipolar Depression Trial (NRX-101)

Learn more

Next


NRX-101 – OUR DRUG IN DEVELOPMENT FOR BIPOLAR DEPRESSION IN PATIENTS WITH ACUTE
AND SUBACUTE SUICIDAL; IDEATION & BEHAVIOR

Learn more about our clinical trial for severe bipolar depression with Sub-Acute
Suicidal Ideation & Behavior (SSIB).

LEARN MORE


LATEST NEWS

November 07, 2022


NRX PHARMACEUTICALS CLOSES $11 MILLION UNSECURED DEBT FINANCING

September 08, 2022


NRX PHARMACEUTICALS LEADERS TO PRESENT AT THE H.C. WAINWRIGHT & CO. 24TH …

August 22, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE
SETTLEMENT OF …

August 15, 2022


NRX PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2022
RESULTS FOCUSING …

December 20, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE CLOSE OF
DEFINITIVE …

December 05, 2022


NRX PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF CARRIE M. CARRETTA, PHD,
APN-BC, AHN-BC, …

December 02, 2022


NRX RECEIVES NASDAQ NOTICE OF LISTING COMPLIANCE

November 14, 2022


NRX PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

November 14, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE EXECUTION
OF DEFINITIVE …

November 10, 2022


NRX PHARMACEUTICALS TO REPORT THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022

November 09, 2022


NRX PHARMACEUTICALS PRODUCES FIRST PHASE 3-STAGE NRX-101 DRUG MADE USING
COMMERCIAL PROCESS

November 08, 2022


NEWS: NRX PHARMACEUTICALS CHIEF SCIENTIST, DR. JONATHAN C. JAVITT ON BIPOLAR
DEPRESSION …

November 07, 2022


NRX PHARMACEUTICALS CLOSES $11 MILLION UNSECURED DEBT FINANCING

September 08, 2022


NRX PHARMACEUTICALS LEADERS TO PRESENT AT THE H.C. WAINWRIGHT & CO. 24TH …

August 22, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE
SETTLEMENT OF …

August 15, 2022


NRX PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2022
RESULTS FOCUSING …

December 20, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE CLOSE OF
DEFINITIVE …

December 05, 2022


NRX PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF CARRIE M. CARRETTA, PHD,
APN-BC, AHN-BC, …

December 02, 2022


NRX RECEIVES NASDAQ NOTICE OF LISTING COMPLIANCE

November 14, 2022


NRX PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

November 14, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE EXECUTION
OF DEFINITIVE …

November 10, 2022


NRX PHARMACEUTICALS TO REPORT THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022

November 09, 2022


NRX PHARMACEUTICALS PRODUCES FIRST PHASE 3-STAGE NRX-101 DRUG MADE USING
COMMERCIAL PROCESS

November 08, 2022


NEWS: NRX PHARMACEUTICALS CHIEF SCIENTIST, DR. JONATHAN C. JAVITT ON BIPOLAR
DEPRESSION …

November 07, 2022


NRX PHARMACEUTICALS CLOSES $11 MILLION UNSECURED DEBT FINANCING

September 08, 2022


NRX PHARMACEUTICALS LEADERS TO PRESENT AT THE H.C. WAINWRIGHT & CO. 24TH …

August 22, 2022


RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE
SETTLEMENT OF …

August 15, 2022


NRX PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2022
RESULTS FOCUSING …

 * 1
 * 2
 * 3


HIGHLIGHTS

As many as 50% of individuals with bipolar disorder attempt suicide or have
serious thoughts of suicide and between 11-20% of those attempt and succumb to
suicide.





Source:
Pallaskorpi, et al. “Incidence and predictors of suicide attempts in bipolar I
and II disorders: A 5-year follow-up study,” Bipolar Disorders, 2016
“Suicide Attempts and Completions in Patients With Bipolar Disorder,”
Psychiatric Times, 2007



NRX-101 is an investigational treatment for bipolar depression in patients with
Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB)


Read more



Today, no medicine is approved to specifically treat bipolar depression in
patients with high levels of suicidal ideation.

NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs:
D-cycloserine, an NMDA receptor modulator; and Lurasidone, a 5-HT2a receptor
antagonist.

READ MORE



DISCOVERY PIPELINE


WE ARE ADVANCING THE DEVELOPMENT OF THE FIRST ORAL INVESTIGATIONAL MEDICINE TO
TREAT BIPOLAR DEPRESSION IN PATIENTS WITH ASIB AND SSIB AND WE ARE EVALUATING
OPPORTUNITIES IN RESPIRATORY DISEASE AREAS.

Each product in our pipeline has potential for additional indications beyond
their initial target indications, and with this, we can save more lives and hope
may become reality for even more people.

Pipeline




WHAT MAKES US DIFFERENT?


WE APPLY INNOVATIVE SCIENCE TO KNOWN MOLECULES.


WE FOCUS OUR EFFORTS TO ADDRESS CRITICAL MEDICAL CONDITIONS THAT ARE NOT BEING
PURSUED OTHERS, SUCH AS SEVERE BIPOLAR DEPRESSION WITH ACUTE SUICIDALITY.

We work to research and develop medicines for people that desperately need them.
We accomplish our mission by directing scientific and clinical expertise towards
innovative clinical protocols.

LEARN MORE


STORIES


APPRECIATING THE VALUE OF A BREATH

One of the tragic results of the pandemic years is the deteriorating mental
health of many Americans — a vicious trend that has spared no one.

Read more




 * Home
 * Our Company
 * Our Science
 * Pipeline
 * Investors / Media
 * Corporate Presentation
 * Resources & Patient Stories

 * Investor Relations
 * Careers
 * Contact Us

 * 
 * 
 * 

 * Forward Looking Statement
 * Privacy Policy
 * Terms of Use

 * © 2023 NRx Pharmaceuticals, Inc.

 * 
 * 
 * 

...


You are leaving the site

The contents of this site are intended for US Healthcare Professionals. Please
certify that you are a healthcare professional by clicking the appropriate link
below.

Yes I am
No I am not
Our website uses cookies to ensure best user experience. View our privacy policy
for more information. By clicking “Accept”, you consent to the use of all
cookies.

Cookie SettingsAccept
Manage consent
Close

PRIVACY OVERVIEW

Our website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the w...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
These cookies ensure basic functionalities and security features of the website,
anonymously.

CookieDurationDescription_wpfuuid11 yearsThis cookie is used by the WPForms
WordPress plugin. The cookie is used to allows the paid version of the plugin to
connect entries by the same user and is used for some additional features like
the Form Abandonment addon.cookielawinfo-checkbox-advertisement1 yearSet by the
GDPR Cookie Consent plugin, this cookie is used to record the user consent for
the cookies in the "Advertisement" category .cookielawinfo-checkbox-analytics11
monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to
store the user consent for the cookies in the category
"Analytics".cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR
cookie consent to record the user consent for the cookies in the category
"Functional".cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookies is used to store the user consent for the
cookies in the category "Necessary".cookielawinfo-checkbox-others11 monthsThis
cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the
user consent for the cookies in the category
"Other.cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookie is used to store the user consent for the
cookies in the category "Performance".CookieLawInfoConsent1 yearRecords the
default button state of the corresponding category & the status of CCPA. It
works only in coordination with the primary cookie.nlbi_1816097sessionA load
balancing cookie set to ensure requests by a client are sent to the same origin
server.viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent
plugin and is used to store whether or not user has consented to the use of
cookies. It does not store any personal data.visid_incap_18160971 yearSiteLock
sets this cookie to provide cloud-based website security services.

Functional
Functional
Functional cookies help to perform certain functionalities like sharing the
content of the website on social media platforms, collect feedbacks, and other
third-party features.

CookieDurationDescription__cf_bm30 minutesThis cookie, set by Cloudflare, is
used to support Cloudflare Bot Management.

Performance
Performance
Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.

CookieDurationDescription_first_pageview10 minutesThis is a session cookie set
during the first display of the page on each visit. This cookie is used to shoot
certain codes on the first display of the page and also to enhance the speed of
the website.

Analytics
Analytics
Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics the number of
visitors, bounce rate, traffic source, etc.

CookieDurationDescription_jsuid1 yearThis cookie contains random number which is
generated when a visitor visits the website for the first time. This cookie is
used to identify the new visitors to the website.cluid1 yearThis cookie is used
for websites which is having multiple domains to identify the same visitor
across multiple domains.CONSENT2 yearsYouTube sets this cookie via embedded
youtube-videos and registers anonymous statistical data.mo_has_visited11
yearsThis cookie is used for setting an unique ID for the visitor which helps to
get the accurate number of specific visitor on the website.mo_is_newsessionThis
cookie is used for counting the new visitors to the website by assigning a
unique visitor ID.mo_page_views_countersessionThis cookie is used for counting
the new visitors to the website by assigning a unique visitor ID.

Advertisement
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and
marketing campaigns. These cookies track visitors across websites and collect
information to provide customized ads.

CookieDurationDescriptionc6 months 2 daysThis cookie is set by Rubicon Project
to control synchronization of user identification and exchange of user data
between various ad services.uuid1 year 27 daysMediaMath sets this cookie to
avoid the same ads from being shown repeatedly and for relevant
advertising.VISITOR_INFO1_LIVE5 months 27 daysA cookie set by YouTube to measure
bandwidth that determines whether the user gets the new or old player
interface.YSCsessionYSC cookie is set by Youtube and is used to track the views
of embedded videos on Youtube pages.yt-remote-connected-devicesneverYouTube sets
this cookie to store the video preferences of the user using embedded YouTube
video.yt-remote-device-idneverYouTube sets this cookie to store the video
preferences of the user using embedded YouTube video.

Others
Others
Other uncategorized cookies are those that are being analyzed and have not been
classified into a category as yet.

CookieDurationDescriptionincap_ses_1371_1816097sessionNo
descriptionunpoco_1013448841 dayNo description

SAVE & ACCEPT



Back
 * Our Company
 * Our Therapeutic Focus
   * Our Focus on the Brain
   * Bipolar Depression & Suicidality
   * Post-Traumatic Stress Disorder
   * Respiratory
 * Our Science
   * Our Clinical Approach
   * NRX-100/NRX-101
   * Mechanism of Action
   * NMDA & 5HT2A receptors
   * Publications & Literature
 * Our Pipeline
 * Investors / Media